

PostScript

LETTERS

If you have a burning desire to respond to a paper published in *Sex Transm Infect*, why not make use of our "eLetters" option?

Log on to the *STI* website (www.stijournal.com), find the paper that interests you, click on [Abstract], or response by clicking on "eLetters submit a response".

Providing your letter isn't libellous or obscene, it will be posted within seven days. You can view recent eletters by clicking on "read eletters" on our homepage.

As before, the editors will decide whether to publish it in a future print issue.

Analysis of *Chlamydia trachomatis* serovar distribution changes in the Netherlands (1986–2002)

Up to 19 different *Chlamydia trachomatis* (CT) serovars which are pathogenic predominantly for the urogenital tract and numerous CT variants have been identified.^{1,2} An increasing number of isolates are typed worldwide and provide a wealth of information on the epidemiology of CT infections, a sexually transmitted disease (STD) for which screening has been proposed.^{3–5} Recent studies have demonstrated an association between CT serovar G and squamous cell carcinoma.⁶ A possible shift in the serovar distribution over time in a region or country could reveal information on changes in the epidemiology

of CT infections and could potentially have clinical implications.

We therefore determined the CT serovar distribution in a large STD population in Amsterdam in 2000–2 and compared it together with all published serovar distributions since 1986 in the Netherlands to assess if serovar distribution shifts over time occurred.

Of people attending the STD outpatient clinic in Amsterdam from 2000–2, those found CT positive ($n = 407$) by LCx (Abbott Laboratories, Chicago, IL, USA) were genotyped as described previously.¹ This is the largest STD population typed to date in The Netherlands. The following serovar distribution was found: B = 1%; D = 12%; Da = 0.2%; D- = 1%; E = 33%; F = 23%; G = 4%; Ga = 5%; H = 8%; I = 6%; Ia = 1%; J = 3%; K = 2%.

Literature searches identified eight serovar distribution studies in the Netherlands, of which the first was performed in 1986. With the inclusion of the present study, 2204 serovars were available for analyses. In the serovar distributions comparison, we (1) did not distinguish between male and female participants, (2) did not distinguish between serovar distributions based on serotyping or genotyping techniques, (3) excluded serovars B/Ba because of the low numbers, (4) excluded double infections, (5) excluded variants, and (6) classified CT serovars in the three phylogenetically based serogroups: the B group (serovars D, Da, D-, E), the intermediate serogroup (serovars F, G, Ga), and the C group (serovars I, Ia, J, Jv, and K).

Results are shown in figure 1. In general, no statistical significant serovar distribution trends in time were observed between 1986 and 2002 when all studies were taken




Figure 1 Serovar distribution studies in the Netherlands from 1986 to 2002. The time of cohort collections is shown since the year of publication can be different from the year of cohort collection. Differences in serovar distributions in time were analysed. Each study is indicated by first author, year of publication, and number of isolates included: 1, Wagenvoort, 1998, $n = 190$; 2, vd Laar, 1996, $n = 372$; 3, Morr , 1998, $n = 90$; 4, Ossewaarde, 1994, $n = 289$; 5, Lan, 1995, $n = 51$; 6, v Duynhoven, 1998, $n = 305$; 7, Morr , 2000, $n = 426$; Morr , 1998, $n = 74$; 9, Spaargaren, this study, $n = 407$. C = serogroup C (serovars H, I, Ia/I', J, Jv, K); Int = intermediate serogroup (serovars F, G, Ga); B = serogroup B (serovars D, Da, D-, E).

Key messages

- No statistically significant serovar distribution shifts were observed between 1986 and 2002 in the Netherlands
- The type of cohort did not influence the analyses: STD based, asymptotically screenings based, mixed cohorts
- Geographical serovar distribution differences were observed between Rotterdam and Amsterdam but these were stable in time:
 - serogroup C was found more frequently in Rotterdam: 30 v 20%, $p < 0.0001$, most prominent serovar difference was serovar K (10.6 v 3.2%, $p < 0.0001$)
 - the Intermediate serogroup was found less frequently: 21 v 31%, $p = 0.0002$, most prominent serovar difference was serovar F (15 v 22%, $p = 0.0018$)
 - serogroup B was stable (49% v 50%)

together. Of the nine studies, 1 and 6 represent serovar distributions from STD populations in Rotterdam and show no significant changes in general or over time (mean: C group: 30%; Int group: 21%; B group: 49%). Studies 2, 3, 4, and 9 represent serovar distributions from STD populations in Amsterdam and show no significant changes (mean: C group: 20%; Int group: 31%; B group: 49%). Studies 5, 7, and 8 represent serovar distributions from mixed symptomatic and asymptomatic infected people (5 and 7) and asymptotically infected populations in Amsterdam. They show no significant changes in general, over time, or compared to the Amsterdam STD based serovar distribution (C group: 17%; Int group: 30%; B group: 53%).

However, when the two geographically derived serovar distributions were compared to each other, (1) serogroup C was found more frequently in Rotterdam: 30 v 19% ($p < 0.0001$; OR 1.8 (95% CI: 1.4 to 2.3)), the most prominent serovar difference was serovar K (10.6 v 3.2%, $p < 0.0001$; OR 3.6 (95% CI 2.4 to 5.3)); (2) the intermediate serogroup was found less frequently in Rotterdam: 21 v 31% ($p = 0.0002$; OR 1.6 (95% CI: 1.2 to 2.0)), the most prominent serovar difference was serovar F (15 v 22%, $p = 0.0018$; OR 1.6 (95% CI: 1.2 to 2.1)), and serogroup B was stable (49% v 50%).

In conclusion, no changes in serovar distribution differences were found over time in the Netherlands in general or within the two different geographic areas. However, the Rotterdam population differed significantly from the Amsterdam populations in having a larger incidence of C group serovars and a lower incidence of the intermediate group serovars, albeit an identical B group serovar distribution. The findings could be the result of different ethnic compositions of the studied cohorts or other confounding factors between Rotterdam and Amsterdam, a subject that warrants further study.

Contributors

JS working on *Chlamydia trachomatis* infections, database management, writing of the manuscript; CS responsible for the statistical analyses; IV and SM, technicians performing all chlamydia typing experiments (culture and PCR based RFLP typing) and sample database management; HSAF, in charge of the STD outpatient clinic in Amsterdam, responsible for the logistics of JS on this topic, critically reviewing the manuscript; ASP and RAC, providing the setting for the work performed, guidance of JS on this topic, and critically reading the manuscript; SAM, responsible for the study design, direct guidance of JS, critically reading the manuscript.

J Spaargaren, I Verhaest, S Mooij

Public Health Laboratory, Municipal Health Service, Amsterdam, Netherlands

C Smit

Cluster Infectious Diseases, Department of HIV and STI Research, Municipal Health Service, Amsterdam, Netherlands

H S A Fennema

Sexual Transmitted Diseases Outpatient Clinic, Municipal Health Service, Amsterdam, Netherlands

R A Coutinho

Municipal Health Service, Amsterdam, Netherlands

A Salvador Peña, S A Morré

Laboratory of Immunogenetics, Section Immunogenetics of Infectious Diseases, VU University Medical Center, Amsterdam, Netherlands

Correspondence to: Joke Spaargaren, MD, Public Health Laboratory, Municipal Health Service of Amsterdam, Nieuwe Achtergracht 100, 1018 WT, Amsterdam, Netherlands; jsaargaren@ggddg.amsterdam.nl

Accepted for publication 5 August 2003

References

- Morré SA, Ossewaarde JM, Lan J, et al. Serotyping and genotyping of genital *Chlamydia trachomatis* isolates reveal variants of serovars Ba, G, and J as confirmed by omp1 nucleotide sequence analysis. *J Clin Microbiol* 1998;**36**:345–51.
- Dean D, Miller K. Molecular and mutation trend analysis of omp1 alleles for serovar E of *Chlamydia trachomatis*. Implications for the immunopathogenesis of disease. *J Clin Invest* 1997;**99**:475–83.
- Gerbase A, Rowley J, Heymann D, et al. Global prevalence and incidence estimates of selected curable STDs. *Sex Transm Infect* 1998;**74**:S12–S14.
- Morré SA, Welte R, Postma MJ. Major improvements in cost effectiveness of screening women for *Chlamydia trachomatis* using pooled urine specimens and high performance testing. *Sex Transm Infect* 2002;**78**:74–5.
- Postma MJ, Welte R, van den Hoek JA, et al. Comparing cost effectiveness of screening women for *Chlamydia trachomatis* in systematic and opportunistic approaches. *Sex Transm Infect* 2002;**78**:73–4.
- Antila T, Saikku P, Koskela P, et al. Serotypes of *Chlamydia trachomatis* and risk for development of cervical squamous cell carcinoma. *JAMA* 2001;**285**:47–51.
- Wagenvoort JHT, Suchland RJ, Stamm WE. Serovar distribution of urogenital *Chlamydia trachomatis* strains in the Netherlands. *Genitourin Med* 1988;**64**:159–61.
- Van de Laar MJ, Lan J, van Duynhoven YT, et al. Differences in clinical manifestations of genital chlamydial infections related to serovars. *Genitourin Med* 1996;**72**:261–5.

- Morre SA, Ossewaarde JM, Lan J, et al. Serotyping and genotyping of genital *Chlamydia trachomatis* isolates reveal variants of serovars Ba, G, and J as confirmed by omp1 nucleotide sequence analysis. *J Clin Microbiol* 1998;**36**:345–51.
- Ossewaarde JM, Rieffe M, de Vries A, et al. Comparison of two panels of monoclonal antibodies for determination of *Chlamydia trachomatis* serovars. *J Clin Microbiol* 1994;**32**:2968–74.
- Lan J, Melgers I, Meijer CJLM, et al. Prevalence and serovar distribution of asymptomatic cervical *Chlamydia trachomatis* infections as determined by highly sensitive PCR. *J Clin Microbiol* 1995;**33**:3194–7.
- Van Duynhoven YT, Ossewaarde JM, Derksen-Nawrocki RP, et al. *Chlamydia trachomatis* genotypes: correlation with clinical manifestations of infection and patients' characteristics. *Clin Infect Dis* 1997;**26**:314–22.
- Morre SA, Rozendaal L, van Valkengoed IGM, et al. Urogenital *Chlamydia trachomatis* serovars in men and women with symptomatic and asymptomatic infection: an association with clinical manifestations? *J Clin Microbiol* 2000;**38**:2292–6.
- Morre SA. *Chlamydia trachomatis* infections in the human urogenital tract. Thesis. 1999;chapter 9.

Surveillance of sexually transmitted infections in primary care

Surveillance for sexually transmitted infections must respond to increases in the provision of sexual health services outside genitourinary clinics. Simms *et al*¹ propose repeated panel surveys in general practices to improve surveillance in primary care, monitor changes in prevalence over time, and address the current lack of behavioural data.

There are some limitations to this approach. Firstly, prevalence surveys will not measure actual diagnostic activity in primary care and other clinical settings. This is essential for determining whether proposals from the National Strategy for Sexual Health² are being implemented effectively. Secondly, periodic surveys in different areas could not readily identify outbreaks. In the Bristol area, for example, most cases in an ongoing outbreak of sexually transmitted hepatitis B infection have presented to general practitioners.³ Although genitourinary medicine clinics are the main setting for detecting outbreaks their impact in primary care should be monitored. Thirdly, the validity of panel surveys will depend on a high response rate and postal invitations often have low uptake.⁴

A single system cannot fulfil all the requirements for infectious disease surveillance. Laboratory reporting remains incomplete⁵ and denominator data need to be available for infections other than chlamydia for appropriate interpretation of time trends. Routine collection of data on laboratory diagnosed sexually transmitted infections from all clinical settings and linkage to demographic data could complement current proposals.

The Avon Surveillance System for Sexually Transmitted Infections (ASSIST) integrates person based genitourinary clinic and laboratory data to provide information for action at local level and to inform national initiatives.⁶ Data on positive and negative tests for laboratory diagnosed infections taken in any clinical setting are collected from the Health Protection Agency and trust laboratories. Postcode information for geographical mapping and small area analysis is obtained by

matching pseudoanonymised data with GP registration databases. These data are also matched to disaggregate data from genitourinary and Brook clinics to identify duplicate tests and obtain geographic data for infections diagnosed in these settings.

ASSIST project data can be used to estimate the population burden of diagnosed infections and explore associations with demographic and socioeconomic characteristics over time. Automating regular data downloads and reporting will improve the timeliness of data collection to facilitate identification and monitoring of outbreaks. The wide coverage of the system can guide local service development and clinical practice and monitor the impact of the Sexual Health Strategy. For example, in 2001 half of all chlamydia tests and 44% of positive results came from GP, family planning, or Brook clinics. Nearly two thirds (62%) of those tested in general practice were over 25 years old in whom the positivity rate was 4% compared with 11% for under 25 year olds.

We propose that, while behavioural data obtained from panel surveys in primary care provide depth, sentinel surveillance of laboratory diagnosed infections in all clinical settings provides breadth, and both are needed for effective surveillance.

W Slater, N Low

Department of Social Medicine, University of Bristol, Canynge Hall, Whiteladies Road, Bristol BS8 2PR, UK

Correspondence to: Dr Nicola Low, Department of Social Medicine, University of Bristol, Canynge Hall, Whiteladies Road, Bristol BS8 2PR, UK; nicola.low@bristol.ac.uk

Accepted for publication 25 July 2003

References

- Simms I, Hurlig A-K, Rogers PA, et al. Surveillance of sexually transmitted infections in primary care. *Sex Transm Infect* 2003;**79**:174–6.
- Department of Health. *National strategy for sexual health and HIV*. London: DoH, 2001.
- Greenhouse P, et al. Leeds: MSSVD Spring Meeting, 12–14 June 2003.
- Andersen B, Olesen F, Moller JK, et al. Population-based strategies for outreach screening of urogenital chlamydia trachomatis infections: a randomized, controlled trial. *J Infect Dis* 2002;**185**:252–8.
- Hughes G, Paine T, Thomas D. Surveillance of sexually transmitted infections in England and Wales. *Eurosurveillance* 2001;**6**:71–80.
- Slater W, Low N for the ASSIST Project Group. *Avon Surveillance System for Sexually Transmitted Infections*. Eastbourne: Faculty of Public Health Medicine Annual Scientific Meeting, June, 2003:24–6.

Comparison of the serological response to treatment of early syphilis in HIV positive versus HIV negative individuals

The effectiveness of treatment for syphilis is evaluated by demonstrating declining titres of the non-treponemal antibody tests—for example, the rapid plasma reagin (RPR). The serological response in HIV co-infected individuals has been the subject of debate, with some studies reporting a similar serological response^{1,2} and others a delayed response in HIV positive patients.^{3,4}

A resurgence of infectious syphilis has occurred in Manchester, United Kingdom, in recent years.⁵ From January 1999 to August 2002, 379 cases of early syphilis were

Table 1 Number of patients in each group and the mean four dilution drop in RPR titres 3, 6, and 12 months following treatment in HIV positive compared to HIV negative individuals

	3 months		6 months		12 months	
	No of patients	Mean drop in RPR	No of patients	Mean drop in RPR	No of patients	Mean drop in RPR
HIV positive	31	1.71	20	2.20	12	2.54
HIV negative	23	1.57	17	2.18	11	3.45
p Value (<i>t</i> test)		0.78		0.97		0.35

reported and 28% were HIV co-infected (CDS North West, personal communication). North Manchester General Hospital (NMGH) houses one of the city's three genitourinary medicine clinics and the regional infectious diseases unit, providing care for approximately 1000 HIV positive individuals. Our aim was to evaluate the serological response to treatment for early syphilis in HIV positive and negative individuals treated at NMGH.

Between January 1999 and March 2002, 75 men (72 homosexual) and three women were diagnosed with early syphilis. Of the 78, 40/75 men were HIV positive. The RPR results 3, 6, and 12 months following treatment for early syphilis were collected by retrospective case note review. Exclusion criteria were syphilis re-infection during the study period (two patients), HIV status undetermined (six patients declined HIV testing), or lost to follow up (16 patients). Patients were divided into two groups—HIV positive and HIV negative individuals. From the sequential RPR results 3, 6, and 12 months following treatment the mean reduction in RPR titres in each group at these points was calculated, and statistical comparison made between the two groups using the Student's *t* test.

The results are shown in table 1.

We found no significant difference in the reduction of RPR titres in the year following treatment between the HIV positive and negative groups.

Of the 31 HIV positive individuals in this study, 17 were taking highly active antiretroviral therapy at the time their syphilis was diagnosed. The average CD4 lymphocyte count in this group was $460 \times 10^6/l$ (range 33–1000) and viral load 83 515 copies/ml (range <50–442 000).

Limitations of the study are that it was retrospective, patients in the HIV positive and negative groups were not matched individually for variables such as stage of syphilis or initial RPR titre, and the treatment regimens varied (all received at least 10 days intramuscular procaine penicillin or 14 days oral doxycycline, and HIV positive patients prolonged courses of treatment in accordance with the UK national guidelines for the treatment of early syphilis⁶). No account was taken of the patient's CD4 lymphocyte count, or whether they were receiving antiretroviral therapy. However, the cohort represents a diverse group of HIV positive individuals and we consider them representative of those generally encountered in clinical practice.

We demonstrated that in clinical practice the RPR remains a valid way of assessing the response to treatment of syphilis in those co-infected with HIV. Larger prospective studies, with cases and controls matched for variables such as the stage of syphilis at diagnosis, the

initial RPR titre, and treatment regimens are required.

M A Kingston, S P Higgins

Department of Genitourinary Medicine, North Manchester General Hospital, Manchester M8 5RB, UK

Correspondence to: Dr M A Kingston, Department of Genitourinary Medicine, North Manchester General Hospital, Delaunays Road, Crumpsall, Manchester M8 5RB, UK; davemags@ntlworld.com

Accepted for publication 1 September 2003

References

- 1 Janier M, Chastang C, Spindler E, *et al.* A prospective study of the influence of HIV status on the seroreversion of serological tests for syphilis. *Dermatology* 1999;198:362–9.
- 2 Goeman J, Kivuvu M, Nzila N, *et al.* Similar serological response to conventional therapy for syphilis among HIV-positive and HIV-negative women. *Genitourin Med* 1995;71:275–9.
- 3 Telzak EE, Greenberg MS, Harrison J, *et al.* Syphilis response in HIV-infected individuals. *AIDS* 1991;5:591–5.
- 4 Yinnon AM, Coury-Doniger P, Polito R, *et al.* Serological response to treatment of syphilis in patients with HIV infection. *Arch Intern Med* 1996;156:321–5.
- 5 Anon. Increased transmission of syphilis in Manchester. *Commun Dis Rep CDR Wkly* 2000;10:89.
- 6 Clinical Effectiveness Group (Association of Genitourinary Medicine and Medical Society for the Study of Venereal Diseases). National guideline for the management of early syphilis. *Sex Transm Infect* 1999;75(Suppl 1):S29–33.

Is it time to rethink the roles of health professionals in the HIV outpatient setting?

HIV outpatient services across the United Kingdom are seeing large increases in their patient workload. This is fuelled by the success of highly active antiretroviral therapy (HAART), resulting in fewer deaths, and by increases in the number of new diagnoses.¹ A further rise is anticipated in England following implementation of "The national strategy for sexual health and HIV" that plans to increase HIV testing dramatically in order to reduce the number of undiagnosed HIV infections by 50% by the end of 2007.² The success of HAART has also changed the focus of many doctor-patient outpatient consultations from prophylaxis and management of opportunistic infections, to issues related to the complexities of HAART, sexual behaviour risk reduction and promoting healthy lifestyles. As a result, HIV service providers need to develop new models of care that can deliver high quality, cost effective care to meet these changing demands. We reviewed

the role of the doctor in providing routine outpatient HIV care.

Data were collected prospectively on all HIV infected patients attending for routine care between 24 June 2002 and 17 July 2002. We obtained complete data for 431 of 433 consecutive patient appointments. Of these, 79/431 (18%) did not attend their appointment. Of the remaining 352, the median age was 38 years (range 17–70), the majority were male (291, 83%), of white ethnicity (251, 71%) with a median CD4 count of $350 \times 10^6/l$ (range 10–1390) and viral load (VL) of 600 copies/ml (range <50–1.2 million).

Consultants saw two thirds of attendees, specialist registrars a third. Almost half the consultations (173/352) were with patients who were defined by their physician as being asymptomatic with respect to their HIV infection; 66/173 (38%) of these were not taking HIV therapy and 107/173 (62%) were on HAART with a sustained virological response (VL<50 for >6 months). Over the next 8 months 53/66 (80%) of those not taking HAART and 68/107 (64%) taking HAART remained well with no significant changes to their health status. Of those on HAART, five required admission to hospital (bacterial pneumonia, three; cholecystitis, one; cryptococcal septicaemia, one), 12 made changes to their therapy (treatment interruption, four; virological rebound, three; toxicity, five) and 12 had intermittent low level viraemia (VL between 50 and 400). Other problems encountered in both groups included shingles (*n* = 7) and raised liver function tests (*n* = 11).

We have identified a high proportion of asymptomatic patients who are currently under regular review by medical staff and could potentially be managed by other healthcare professionals. Increased use of general practitioners and nurse practitioners are two potential options. We should review HIV outpatient service provision and move away from the "acute-terminal" model of care that has prevailed since the beginning of the epidemic and learn from chronic disease management models seen in other areas of the health service. As these new models are developed, in addition to staff requiring training to be conversant with common problems seen during routine monitoring of antiretroviral therapy, it is essential that evaluation is conducted to ensure similar levels of effectiveness, efficiency, and acceptability.

Contributors

SE and DM developed the study; SE, SD, and CG collected and analysed the data; SD and KM wrote the text. SE, DM, and CG provided comments on the text.

S S Dave

Mortimer Market Centre, Camden Primary Care Trust, London WC1E 6AU, UK

K Miles, C Griffiths, D E Mercey

Department of Sexually Transmitted Diseases, Royal Free and University College Medical School, University College London, UK

S G Edwards

Mortimer Market Centre, Camden Primary Care Trust, London WC1E 6AU, UK

Correspondence to: Dr Sangeeta S Dave, Mortimer Market Centre, Camden Primary Care Trust, London WC1E 6AU, UK; sangeeta.dave@camdenpct.nhs.uk

Funding: None.

Competing interests: None declared.

References

- 1 **PHLS Communicable Disease Surveillance Centre, ICH (London), SCIEH.** *HIV and AIDS in the United Kingdom 2001*. London: an update November, 2002.
- 2 **Department of Health 2001.** *The national strategy for sexual health and HIV*. London: DoH, 2001.

Syphilis outbreak in Milan, Italy

Infectious syphilis has been considered a sensitive marker of risky sexual behaviour.¹ Following a decline of syphilis in Western Europe,^{2,3} there has been a resurgence of infectious syphilis in many countries, with a number of outbreaks in men who have sex with men (MSM).^{4,5}

The STD centre of Milan is the biggest in northern Italy with an average of about 6000 patients per year. All patients are offered screening tests for syphilis using treponemal particle agglutination test (TPPA) and rapid plasma reagin (RPR).

The number of cases of early syphilis (primary, secondary, and early latent asymptomatic with probable infection <12 months previously) has increased from 46 to 211 between 2000 and 2002. Over the same time the number of cases of late syphilis (asymptomatic with probable infection >12 months previously) have remained stable. Most cases of early syphilis in 2001 and 2002 (261/306, 85%) were in MSM. Fig 1 shows the trends.

As in other reports of recent syphilis outbreaks in MSM, a proportion of cases (25.8%) are in men with HIV.⁶ Of the 74 HIV positive men with early syphilis, 39 (53%) already knew their HIV status. This is an indication that our health promotion messages are not effective with this group at least.

The fear of AIDS has declined in Italy: public campaigns are soft, HAART therapy has changed the appreciation of HIV infection in infected patients, and HIV is no longer considered a fatal condition.

M Cusini, M Ghislanzoni, C Bernardi, G Carminati, R Zerboni, E Alessi

Centro MTS, Istituto di Scienze Dermatologiche, IRCCS Ospedale Maggiore, Milano, Italy

B Suligoi

Istituto Superiore di Sanità, Roma, Italy

Correspondence to: Dr Marco Cusini, Centro MTS, Istituto di Scienze Dermatologiche, Via Pace 9, 20122 Milano, Italy; m.cusini@policlinico.mi.it

Accepted for publication 28 September 2003




Figure 1 Trend of early syphilis per sexual behaviour 1999, 2000, 2001, and 2002.

References

- 1 **Pinkerton S, Layde PM.** Using sexually transmitted disease incidence as a surrogate marker for HIV incidence in prevention trials: a modelling study. *Sex Transm Dis* 2002;**29**:298–307.
- 2 **Nicoll A, Hamers FF.** Are trends in HIV, gonorrhoea, and syphilis worsening in western Europe? *BMJ* 2002;**324**:1324–7.
- 3 **St Louis ME, Wasserheit JN.** Elimination of syphilis in the United States. *Science* 1998;**281**:353–4.
- 4 **Weir E, Fishman D.** Syphilis: have we dropped the ball? *CMAJ* 2002;**167**:1267–8.
- 5 **Halsos AM, Edgardh K.** An outbreak of syphilis in Oslo. *Int J STD AIDS* 2002;**13**:370–2.
- 6 **Blocker ME, Levine WC, St Louis ME.** HIV prevalence in patients with syphilis, United States. *Sex Transm Dis* 2000;**27**:53–9.

Online HIV/STI Chinese clinician training

The spread of HIV in China is accelerating and many Chinese physicians are poorly trained to address it.¹ We review clinician training and the internet in China, and present the results of a convenience sampling of 136 Chinese clinicians regarding their access and attitudes towards computer based HIV/STI training.

Having been trained in an era of virtual STI eradication, many Chinese physicians are inadequately prepared to respond to the current HIV epidemic.² Medical school curricula frequently lack STI coursework, and a European Union-China Project (EUCP) study in 2000 showed as few as 5% of physicians had ever received any HIV/STI training.³ Coinciding with the spread of HIV in China is the exponential growth of the internet and computer technology, reaching over 68 million internet users as of June 2003.⁴ These computer based resources can potentially serve as a powerful medium for the training of clinicians.

To investigate this opportunity, we adapted Chinese language HIV/STI materials developed by the EUCP to create an online HIV/STI training page for the website of the Chinese National AIDS Prevention and Control Center (www.aids.net.cn). We then presented the site and distributed paper based surveys to 136 clinicians recruited during STI training courses in several urban areas.

The response rate was 97% (132/136). Among those sampled, 95% reported having computer access and 86% reported having internet access, defined as access at home, work, or internet cafes. Similar access levels were reported by the subset of respondents (17%) who reported having had no HIV/AIDS training in medical school or in continuing medical education (CME). All 132 respondents reported a willingness to utilise computer based training.

This study found a surprisingly high level of computer and internet access among a convenience sample of STI specialists from several urban areas in China. The main limitation of this study was the non-representative sampling, which makes generalisation to other Chinese physicians difficult. Despite this, we believe that these results can be cautiously applied to significant numbers of urban Chinese clinicians who share similar levels of access and interest with this study population.

Online CME presents a promising way to take advantage of growing computer/internet access in China. Chinese physicians can already obtain many of their required CME credits online, with the largest site (www.cmechina.net) training over 50 000 users annually.⁵ Notably, HIV/AIDS training is not available.

Other potential uses of computer/internet resources include creating training centres to serve as clearing houses for up to date training materials. Especially in those areas where extreme geographic barriers limit the scope of traditional training methods, the internet can help remote hospitals and physicians engage in distance learning.

As China strives to control a growing HIV epidemic with a limited budget, low cost/high output resources like computer/internet training cannot be overlooked.⁶ While further investigation is needed to show training efforts positively affect outcomes, the computer/internet revolution offers an immediate and cost effective opportunity to train many urban and some rural physicians. This study suggests that the technical access and clinician willingness necessary for such HIV/STI training may already exist.

J D Tucker, C Jia, G E Henderson, M S Cohen
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

J A Davis

University of California at San Francisco, San Francisco, CA, USA

X C Wang

Chinese Centers for Disease Control, Beijing, China

Correspondence to: Joseph D Tucker, UNC School of Medicine, University of North Carolina at Chapel Hill, Mailbox 346, CB 7000, Chapel Hill, NC 27599-7000, USA; Joseph_Tucker@med.unc.edu

Accepted for publication 18 September 2003

References

- 1 **Zhuang K, Gui X, Su B, et al.** High prevalence of HIV infection among women and their children in Henan Province, China. *J AIDS* 2003;**33**:649–50.
- 2 **Cohen MS, Ping G, Fox K, et al.** Sexually transmitted diseases in the People's Republic of China in Y2K; back to the future. *Sex Transm Dis* 2000;**27**:143–5.
- 3 **Xia Q, Yang P, Wei X, et al.** STD/AIDS training for medical college students in China. *Int J STD AIDS* 2001;**12**(Suppl 2):203.
- 4 **China Internet Network Information Center.** *Analysis report on the growth of the internet in China*. [Online] www.cnnic.net.cn (accessed 1 September 2003).
- 5 **Chinese Ministry of Health.** [Implementation of distance learning and internet-based continuing medical education.] Chinese. 29 December 2000 [Online] www.cmechina.net/html/zhengce/wenjian_007.htm (accessed 20 July 2003).
- 6 **Garbus I, Chatani M, Peiperl L, et al.** Is the Internet relevant to addressing HIV/AIDS in poor countries? The IV International AIDS Conference, Barcelona, July 2002. Abstract 5586.

Treatment of vulval vestibulitis with a potent topical steroid

Vulval vestibulitis (vestibulodynia) is characterised by penetrative introital pain and erythema and tenderness localised to the vestibular glands.¹ The aetiology is unknown and most treatment strategies are based on anecdote.^{2–5} Some clinicians recommend the use of a topical steroid but there are no published data to support this.

We designed a randomised double blind crossover study to compare a potent topical steroid, Dermovate ointment (clobetasol propionate 0.05%), with a very mild steroid, 0.5% hydrocortisone ointment. The hydrocortisone acted as a placebo as it was impossible to obtain a matching placebo for Dermovate ointment. To demonstrate a 20% difference

between Dermovate and hydrocortisone treated episodes if the placebo effect was 40%, 110 patients were needed. Unfortunately, recruitment was slow and the study ended when the expiry date of the medications was reached.

This report describes the outcomes in the patients who participated. The ethics committee of Mount Vernon and Watford Hospitals NHS Trust approved the study; patients gave written informed consent. All patients had introital pain, tenderness, and erythema compatible with a diagnosis of vulval vestibulitis. The study comprised three phases:

- (1) emollients only for 2–8 weeks,
- (2) tube one of the study medication, applied to the vestibule each night for 28 nights,
- (3) tube two of medication used similarly.

The tubes were identical and the study was designed so that within blocks of 10 patients, half would use each medication first. The same clinician assessed each patient at 14 day intervals using a three point scale for each of the parameters—pain, tenderness, and erythema (maximum score 9; minimum score 0 for each visit). The scores obtained at entry (minimum 3) and after each phase were noted.

Twenty two patients were recruited, but some patients withdrew or were excluded for protocol violations. Fourteen patients completed all phases of the study and two completed the first two phases. After emollient use, nine patients had improved (mean score -1.1 ; range -0.5 to -2); after Dermovate, 11 improved (mean score -2.7 ; ranges -0.5 to -8); and after hydrocortisone nine improved (mean score -1.8 ; range -1 to -3) (table 1). Eight patients who used both treatments had a better response to Dermovate and four had a better response to hydrocortisone ($p < 0.07$). Eight patients expressed a definite preference, seven for Dermovate and one for hydrocortisone. There may, however, have been an effect of the order of the treatments as two patients did better on their first treatment whereas nine did better on their second ($p < 0.06$).

Although this study was not completed, some conclusions can be reached. Short term use of a potent topical steroid preparation did not produce a clinically important improvement in all cases but some patients had very good responses, which were maintained. This may reflect the fact that the aetiology of vulval vestibulitis is multifactorial and where there has been an inflammatory, infective, or irritant cause, topical steroids may be helpful. There is an urgent need to identify and classify the causes of this syndrome so that appropriate treatment can be targeted more accurately.

Acknowledgements

I wish to thank Glaxo-Wellcome (now Glaxo-Smith Kline) for the supply of the study medication.

Table 1 Treatment outcomes

	Emollient	Dermovate ointment	Hydrocortisone ointment
Improved	9	11	9
Unchanged	5	2	1
Worse	2	2	5

P E Munday

Watford Sexual Health Centre, Watford General Hospital, Vicarage Road, Watford, WD18 0 HB, UK; pat.munday@whht.nhs.uk

doi: 10.1136/sti.2003.007328

Accepted for publication 6 December 2003

References

- 1 McKay M, Frankman O, Horowitz BJ, *et al*. Vulvar vestibulitis and vestibular papillomatosis. *J Reprod Med* 1991;**36**:413–15.
- 2 Boardman LA, Peipert JF. Vulvar vestibulitis: is it a defined and treatable entity? *Clin Obstet Gynecol* 1999;**42**:945–956.
- 3 Friedrich EG Jr. Therapeutic studies on vulvar vestibulitis. *J Reprod Med* 1988;**33**:514–18.
- 4 Peckham BM, Maki DG, Patterson JL, *et al*. Focal vulvitis: a characteristic syndrome and cause of dyspareunia. *Am J Obstet Gynecol* 1986;**154**:855–64.
- 5 Green J, Christmas P, Goldmeier D, *et al*. A review of physical and psychological factors in vulvar vestibulitis syndrome. *Int J STD AIDS* 2001;**12**:705–9.

Unexpected resistance in an African immigrant: lessons for the unwary

The number of people emigrating from Africa to the United Kingdom has been escalating. They contribute to the increasing number of heterosexuals with HIV in the United Kingdom.¹ Increasingly, developing countries are improving their access to antiretroviral drugs through global funds for AIDS and other sources. It is well known that resistance to antiretrovirals develops where therapy is either suboptimal or adherence is imperfect, and that such resistance is associated with poor outcome.²

A Zimbabwean man aged 47 was admitted to the Royal Sussex County Hospital, in August 2001 with lobar pneumonia. He had excellent response to the appropriate antibiotics. He reported receiving treatment for tuberculosis twice in the past. He had a positive HIV antibody test which was done after pretest discussion. The baseline CD4 count and viral load were consistent with advanced infection, $20 \times 10^9/l$ (2%) and 134 000, respectively.

He was commenced on combination antiretroviral therapy with combivir and efavirenz, and had a good initial virological response with a drop of his viral load to 1230 (3.09 logs) in 2 weeks. However, his viral load rebounded to 71 000 at 6 weeks. He was thought to be non-adherent to the antiretrovirals at this stage and was questioned extensively regarding adherence. He claimed 100% adherence to his medication and denied any missed or late doses. Interactions with prescribed and non-prescribed medications were excluded.

At this stage a genotypic resistance test was organised from the sample, with a viral load of 71 000 and he was admitted to the local respite unit (The Sussex Beacon) for directly

observed therapy (DOT). The viral load after 2 weeks of DOT was 240 000.

A genotypic resistance test revealed the following mutations: K65R, D67N, K70R, K103N, M184V, G190A, T215F, K219Q, suggesting that he had extensive resistance to nucleoside analogues and to all non-nucleosides. When he was reviewed with his resistance test result, he still denied any knowledge of HIV testing or treatment in Zimbabwe, but identified combivir tablets as part of his anti-tuberculosis medication. Genotypic resistance testing of his archived initial sample before his commencement of treatment showed: M41L, V118I, M184V, T215F.

He was then commenced on a salvage regimen of didanosine, tenofovir, kaletra, and saquinavir HG and had a good virological response with a viral load drop of 1350 (3.13 logs) in 4 weeks.

It remains uncertain whether in this case the individual had been aware of his HIV status. It is possible that antiretroviral medications may have been included as part of an unorthodox anti-tuberculosis regimen, given the high co-infection rate in Zimbabwe, without the individual having been informed. Alternatively, the individual may have been unwilling to disclose his status for fear of rejection of his legal claim to stay in the United Kingdom or for other sociocultural reasons.

Either way, the choice of initial therapy was inappropriate, given the underlying resistance to reverse transcriptase analogues, and resulted in the subsequent rapid accumulation of NNRTI resistance.

While it is known that acquired resistance mutations may disappear with time after discontinuation of therapy³ had a genotype resistance test been performed at presentation in this case a more effective regimen would have been selected. Current BHIVA guidelines recommend resistance testing before therapy only in the context of demonstrable transmitted drug resistance.

As antiretroviral therapies become increasingly available in developing countries and while stigma regarding disclosure of HIV status for immigrants remains, we believe that similar cases will occur.

We strongly suggest that immigrants with a new HIV diagnosis should be closely questioned regarding previous testing and treatment, and also baseline resistance testing should be routinely considered.

U R Natarajan, M Fisher

Brighton and Sussex University Hospitals NHS Trust, Brighton, UK

Correspondence to: U R Natarajan, Brighton and Sussex University Hospitals NHS Trust, Brighton, UK; ushawrite@aol.com

doi: 10.1136/sti.2003.007542

Accepted for publication 3 November 2003

References

- 1 Unlinked Anonymous Surveys Steering Group. *Prevalence of HIV and hepatitis infections in United Kingdom 2001*. London: Department of Health, 2001.
- 2 DeGruttola V, Dix L, D'Aquila, *et al*. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardised data analysis plan. *Antiviral Therapy* 2000;**5**:41–8.
- 3 Devereux HL, Youle M, Johnson MA, *et al*. Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. *AIDS* 1999;**13**:F123–7.

Increased uptake of HIV screening following introduction of "opt out" testing and results by telephone

Rogstad *et al*¹ showed an increase both in the number of patients who were offered the HIV test and those who took the test following the use of a leaflet. We report the increased uptake rate of HIV testing since the introduction of "opt out" testing and giving results by phone.

Before January 2002, patients attending our clinic were offered an HIV test if they belonged to high risk groups such as men who have sex with men or injecting drug users. Pretest counselling was done by our health advisers and patients were required to return to the clinic to receive their test results. In 2001, 904 of 2930 new and re-registered patients (31%) underwent HIV testing.

The UK government's national strategy for sexual health and HIV set its target for reducing undiagnosed HIV in genitourinary medicine clinics by increasing the uptake of HIV testing to 40% by the end of 2004 and to 60% by the end of 2007.²

From 1 January 2002, we introduced an "opt out" system, whereby all patients were offered HIV tests, regardless of risk category. This led to an increase in HIV test uptake in the following 3 months to 37% (272 of 740 new patients).

This caused an increase in the workload of our health advisers, who were spending much time in pretest counselling low risk patients and giving negative HIV results. It became clear that exhaustive, in-depth HIV pretest counselling was impractical and inappropriate when the majority of those tested were "low risk." Accordingly, we decided that only high risk patients should be referred pretest to the health advisers.

It was also observed that some patients who initially agreed to undergo HIV testing changed their minds when they learned that they would be required to return to the clinic to collect their result. We decided to offer HIV results by telephone, in line with our policy for all other screening tests. High risk patients, however, were encouraged to attend in person for their result. In the next 3 months 44% (293 of 663 new patients) took HIV tests. Five patients tested HIV positive, but only one received the result by telephone.

The introduction of a telephone HIV results system enabled us to exceed the Department of Health target for 2004. The new system was adopted after consideration of the pros and cons in a departmental meeting in which the opinions of all staff were canvassed. Some concern was expressed about the potential for self harm by patients given bad news outside the clinical setting. We tried to minimise such outcomes by encouraging patients to telephone in the presence of their partner, a friend, or a relative. Results were only given by telephone when the patient could be seen in clinic on the following day at the latest.

The telephone results system is very popular. One patient said, he would far rather receive bad news in the familiar surroundings of home, with the support of his partner, than in a clinic.

We do not know if it is psychologically harmful (or indeed beneficial) for patients to receive a positive HIV result by telephone; research is needed to answer this question. Given the drive to reduce the number of people with undiagnosed HIV infection and the demands of working life, we believe telephone results are here to stay.

M Mahto, S P Higgins

Department of GU Medicine, North Manchester General Hospital, Manchester M8 5RB, UK

Correspondence to: Dr M Mahto, Genitourinary Medicine Department, Stepping Hill Hospital, Stockport, SK2 7JE, UK; drmahto@onetel.net.uk

Accepted for publication 8 October 2003

References

- 1 Rogstad KE, Bramham L, Lowbury R, *et al*. Use of a leaflet to replace verbal pretest discussion for HIV: effects and acceptability. *Sex Transm Infect* 2003;**79**:243–5.
- 2 Department of Health. *The national strategy for sexual health and HIV*. London: DoH, 2001 (www.doh.gov.uk/nshs).

CD-ROM REVIEW

Topics in International Health: Sexually Transmitted Infections, 2nd ed

Institutional licence £120; individual licence £30; developing world licence £20. CD-Roms are not Apple Mac compatible. Disc adviser: Dr J E Richens, Department of Sexually Transmitted Diseases, Royal Free and University College London Medical School, UK. London: The Wellcome Trust, 2003. ISBN 0 85199 631 0.

Having previously resisted the temptation to upgrade from printed text to the 21st century I was suitably impressed by both the technical design and the factual content of this 2nd edition CD-Rom. As a bit of a computer novice I found the software easy to install and navigate with helpful instructions at the touch of a button. The program itself runs on Windows 95, 98, 2000, NT4, or XP and needs 32MB of RAM with at least a 120 MHz Intel Pentium processor (or equivalent).

The CD-Rom provides a vast wealth of information on all aspects of common and tropical STIs that are presented in the form of 18 interactive tutorials, each reviewed by expert authors, and a collection of about 800 images. The material covered ranges from history taking and clinical examination to epidemiology, laboratory diagnosis, and syndromic management of STIs. It includes in-depth tutorials on individual STIs that provide up to date references on management useful both in the developing and developed world. HIV/AIDS is covered in a separate CD-Rom. However, there is detailed mention here of epidemiological synergy with common STIs and trials exploring control of STIs to reduce transmission of HIV.

The 18 tutorials consist of 50–70 slides on each topic. The CD-Rom is therefore topic led with no search facility for those wishing to access a list of differential diagnoses by symptoms and signs. The user's attention span is maximised by a mixture of high quality images interspersed with relevant yet concise text and a useful summary of all sections. Interactive quizzes and diagrams help to reinforce learning and a notepad is strategically placed for users wishing to go back to basics and include their own free text. A glossary is available on each page should any terms need further clarification and all text is fully referenced. The pictures used in all the tutorials appear chronologically in the

image collection and can be printed. They can also be sorted and saved in groups of your choice. The only hitch is that they can't be downloaded into presentations, personal slide libraries, or palm pilots—shame!

The detail presented is still not enough to rival textbooks such as King Holmes's *Sexually Transmitted Diseases* but this is not the purpose of the CD-Rom. It is ambitiously designed for use as an educational resource in both developed and developing countries and I think it serves this purpose well. Its appeal spans a broad range: medical students swatting for exams (and SpRs sitting Dip GUM!), academic researchers as a useful point of reference and all healthcare professionals involved in direct clinical care of patients with STIs including nurses and health advisers.

Overall, the CD-Rom provides an interactive way of accessing and assimilating a huge amount of information on all aspects of STIs. It is definitely much more user friendly than lugging a huge textbook around and gets a big thumbs-up from me!

K P Prime

NOTICE

8th European Society of Contraception Congress

The 8th European Society of Contraception Congress will be held from 23–26 June 2004 in Edinburgh, Scotland, UK. For further details please contact ESC Central Office, c/o Orga-Med Congress Office, Essenestraat 77, B-1740 Ternat, Belgium (tel: +32 2 582 08 52; fax: +32 2 582 55 15; email: orgamed.ann@pandora.be; and website: <http://www.contraception-esc.com/edinburg.htm>).

CORRECTION

There is an error in table 3 of the paper by Pimenta *et al* (J M Pimenta, M Catchpole, P A Rogers, J Hopwood, S Randall, H Mallinson, E Perkins, N Jackson, C Carlisle, G Hewitt, G Underhill, T Gleave, L McLean, A Ghosh, J Tobin, V Harindra. Opportunistic screening for genital chlamydial infection. II: Prevalence among healthcare attenders, outcome, and evaluation of positive cases. *Sex Transm Inf*, 2003;**79**:22–27).

The statistical calculation of this table combined all women, regardless of age. The authors have recalculated this table, and the revised version is available on the website (<http://sti.bmjournals.com/cgi/data/79/1/22/DC1/1>) with the correct age restriction — female participants 16 to 24 years only, as originally specified. The majority of these data (general practice, family planning, and youth clinics) have only changed marginally; the main differences lie within the GUM clinics, due to the wider age of women tested at this setting. The conclusions, however, are unaffected by this error. The authors stand by their assertion that prevalence tends to be higher in those reporting and attending with symptoms than those screened opportunistically.